Below are the Posters Focusing on ILC Research that will be presented Wednesday Morning. Each is listed under the name of its specific Poster Session (PS).
Wednesday 8:00 am
PS 2 – Markers, Pathology
PS2-12 Can oncotype Dx risk categories be predicted in invasive lobular carcinoma?
Glasgow A, Sechrist H, Bomeis P, Gilmore H, Harbhajanka A. University Hospitals Cleveland Medical
Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH.
PS 4- Response Prediction Biomarkers I
PS4-23 An analysis of the clinical and economic impact of the 21-gene recurrence score (RS) in invasive lobular early-stage breast cancer (ESBC) in Ireland
Tharmabala M, McSorley L, Al Rahbi F, Denis E, Geraghty JG, Jane R, McCartan D, McDermott E,
Keane MM, Kennedy J, O’Reilly S, Millen S, Crown J, Smyth LM, Kelly CM, Ruth P, Quinn C, Walshe
JM. St. Vincents University Hospital, Dublin, Ireland; Galway University Hospital, Galway, Ireland; St.
James Hospital, Dublin, Ireland; Cork University Hospital, Dublin, Ireland; Exact Sciences UK Ltd,
London, United Kingdom; Mater Misericardiae University Hospital, Dublin, Ireland.
PS 6 – Prognostic Factors
PS6-11 Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: Validation using a novel gene signature of HER2 activation
Alsaleem M, Kurozumi S, Bhardwaj K, Monteiro C, Joosten SEP, Green AR, Fujii T, Shirabe K, Ellis IO,
Rakha EA, Mongan NP, Heery DM, Zwart W, Oesterreich S, Johnston SJ. University of Nottingham,
Nottingham, United Kingdom; Gunma University Graduate School of Medicine, Gunma, Japan;
Netherlands Cancer Institute, Amsterdam, Netherlands; Womens Cancer Research Center, UPMC
Hillman Cancer Center and Magee-Women Research Institute, Pittsburgh, PA; AstraZeneca, Cambridge, United Kingdom.
PS 7 – Epidemiology
PS7-15 Mixed Invasive ductal lobular carcinomas (mDLC) are clinically more similar to invasive lobular carcinoma (ILC) than to invasive ductal carcinoma (IDC)
Nasrazadani A, Li Y, Fang Y, Shah O, Atkinson JM, Lee JS, McAuliffe PF, Lee AV, Tseng G, Lucas P,
Oesterreich S, Wolmark N. UPMC Hillman Cancer Center, Magee-Womens Research Institute,
Pittsburgh, PA; University of Pittsburgh, Department of Biostatistics, Pittsburgh, PA; University of
Pittsburgh, Magee-Womens Research Institute, Pittsburgh, PA; University of Pittsburgh, Department of
Surgery, Pittsburgh, PA; University of Pittsburgh, Department of Surgery, Magee-Womens Research
Institute, Pittsburgh, PA; Unviersity of Pittsburgh, Department of Pathology, NSABP, Pittsburgh, PA;
University of Pittsburgh, Department of Surgery, NSABP, Pittsburgh, PA.
PS 8 – Risk Factors and Prevention
PS8-06 Survival outcomes after chemotherapy in invasive lobular carcinoma compared to
estrogen receptor positive invasive ductal carcinoma Timbres J, Moss C, Mera A, Haire A, Gillett C, Van Hemelrijck M, Sawyer E. King’s College London,
London, United Kingdom.
PS 11 – Systemic Therapies II – New
PS11-02 Comprehensive comparative analysis of invasive ductal and lobular breast cancer
cases in Great Lakes Breast Cancer Consortium
Oesterreich S, Nasrazadani A, Zou J, Onger T, Wright M, Tseng G, Ramaswamy B, Lee AV, Williams N,
Kruse M. UPMC Hillman Cancer Center, University of Pittsburgh, Magee Womens Research Institute,
Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA;
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute,
Cleveland, PA; James Cancer Hospital/The Ohio State University Wexner Medical Center (OSU),
Columbus, OH; James Cancer Hospital/The Ohio State University Wexner Medical Center (OSU),
Columbus, PA.
PS11-16 Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL
Thill M, Zahn M-O, Welt A, Stickeler E, Nusch A, Fietz T, Rauh J, Wetzel N, Kruggel L, Jänicke M, Marschner N,
Harbeck N, Wöckel A, Decker T, OPAL study group. Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany; Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation Harz, Goslar, Germany; Universitätsklinikum Essen Innere Klinik Tumorforschung, Essen,
Germany; Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin, Aachen, Germany;
Praxis für Hämatologie und internistische Onkologie,Ratingen, Germany;
Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie,
Singen(Hohentwiel), Germany; GIM – Gemeinschaftspraxis Innere Medizin,
Witten, Germany; iOMEDICO, Freiburg,Germany; Praxis für interdisziplinäre
Onkologie & Hämatologie, Freiburg, Germany; Klinikum der UniversitätMünchen,
München, Germany; Universitätsklinikum Würzburg Frauenklinik und Poliklinik,
Würzburg, Germany Studienzentrum Onkologie Ravensburg, Ravensburg, Germany.
PS 17 Tumor Biology II
PS17-05 Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast
Rothschild H, Esserman L, Benz C, Mukhtar R. UCSF, San Francisco, CA.
PS17-27 Molecular evaluation of immunogenicity and genomic alterations in invasive lobular breast cancer
Giri U, Xiu J, Karadimitriou T, Castanon S, Ademuyiwa F, Pohlmann P, Obeid E, Sachdev J,
Krill-Jackson E, Simon M, Tan A, Denduluri N, Schwartzberg L, Korn M, Roussos Torres ET. University
of Southern California, Los Angeles, CA; Caris Life Sciences, Phoenix, AZ; Washington University, St.
Louis, MO; Lombardi Comprehensive Cancer Center, George town University, Baltimore, MD; Fox
Chase Comprehensive Cancer, Philadelphia, PA; Honor Health, Scottsdale, AZ; University of Miami,
Miami, FL; Karmanos Cancer Institute, Detroit, MI; Atrium Health, Charlotte, NC; US Oncology,
Arlington, VA; West Clinic, Memphis, TN.
PS 18 Tumor Biology III
PS18-03 Differential gene expression in Luminal-type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
Lesnikoski B-A , Crozier JA, Srkalovic G, Robinson P, Osipo C, Banda K, Kling HM, Haan J, Audeh W,
FLEX Investigators Group. Baptist MD Anderson Cancer Center, Jacksonville, FL; Herbert-Herman
Sparrow Cancer Center, Lansing, MI; Loyola University Chicago, Stritch School of Medicine, Maywood,
IL; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; Medical Affairs,
Agendia, Inc., Irvine, CA; Research and Development, Agendia NV, Amsterdam, Netherlands.
PS18-41 Somatic mutational landscapes of invasive ductal and lobular carcinomas in the GENIE consortium cohort: Real-world gene actionability assessment of 8,756 breast cancer patients
Leal A, Taranto P, Blasi PBG, Garrote CT, Moura F. Hospital Israelita Albert Einstein, Sao Paulo, Brazil;
Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil.
PS 19 – Tumor Biology IV
PS19- Role of the calcium-sensing recepton (CaSR) in invasive lobular breast carcinoma metastasis to the ovary
Qin Y, Savariau L, Basudan AM, Shah O, Li Z, Liu T, Tasdemir N, Coffman L, Elishaev E, Atkinson JM,
Lucas P, Lee AV, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; Tsinghua University, Beijing,
China; Magee Women’s Hospital, Pittsburgh, PA.
Thursday 3:30pm -4:45pm
Posters in the Spotlight Session
PD6-08 DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy
Tran G, Jones E, Li W, Fahrner-Scott K, Newitt D, Joe B, Esserman L, Hylton N, Mukhtar R. Boston
Medical Center, Boston, MA; UCSF, San Francisco, CA.
PD6-10 18F-fluoroestradiol (fes) and 18f-luorodeoxyglucose (fdg) pet imaging in
metastatic lobular breast cancer
Manohar P, Peterson L, Wu V, Jenkins I, Muzi M, Specht J, Chen D, Link J, Krohn K, Kinahan P,
MankoffD, Linden H. University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Oregon Health Sciences University, Portland, OR; Oregon Health Sciences University, Portland, Portland, OR; University of Pennsylvania, Philadelphia, PA.
